Navigation Links
NWBT Highlights Cost Effectiveness of DCVax® in View of Recent Immunotherapy Pricing Concerns
Date:8/10/2011

BETHESDA, Md., Aug. 10, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) reminded markets, in response to recent investor concerns about Dendreon's Provenge immune therapy, that NWBT's DCVax® immune therapies for a broad range of cancers (including prostate, brain, ovarian and others) hold the promise, based on available data to date, of being cost effective and priced below other immune therapies while still providing substantial profit margins for the Company and longer survival for patients.  

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

The investor concerns in the news relate to the pricing and reimbursement of Provenge for late stage, metastatic prostate cancer.  Provenge is priced at $93,000 for one month of treatment and was approved by the FDA based upon having added 4.5 months of patient survival (to reach overall survival of 25.9 months).  

NWBT's DCVax® will be priced in the range of $37,000 per year for up to 3 years of treatments.  In NWBT's Phase I/II multi-center clinical trial in late stage, metastatic prostate cancer, DCVax® added 18 months of patient survival (to reach overall survival of 38.7 months).  DCVax® has previously been cleared by the FDA for a 612-patient, randomized, controlled Phase III trial, although the trial has not yet begun.  As is typical before a Phase III trial, the manufacturing processes and product costs have already been determined.

Linda Powers, Chairman of the NWBT Board and CEO commented that  "It is really important that  pricing and reimbursement concerns associated with certain immune therapies, such as Provenge, not cause a disillusionment with all of the emerging immune therapies for cancer. Some of these, such as DCVax®, while at an earlier stage of development, continue to prog
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment
2. CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results
3. Isis Reports Financial Results and Highlights for Second Quarter 2011
4. Bionovo Announces Second Quarter 2011 Highlights and Financial Results
5. Thomas Publishing Expands Brand Information and Highlights Its Career Center on a New Company Website
6. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
7. Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches
8. Hospira Highlights Progress in 2010 at Its 2011 Annual Meeting of Shareholders
9. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
10. Isis Reports Financial Results and Highlights for First Quarter 2011
11. Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
(Date:10/22/2014)... Oct. 21, 2014 Influenza will affect as many ... the United States as high as ... to spread is from person to person in respiratory droplets ... serve way of death, but kills much fewer people each ... done by human fluids including sweat, saliva, blood and other ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 WHEN: ... EDTLOCATION: Online, complimentary registration available at: ... Leader Archana Vidyasekar and Visionary Innovation Research ... WiFi-like wireless electricity, self-assembling materials, nanobots and ... technologies which will transform our lives in ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 More ... annual President’s Circle Reception on Monday at the home ... accomplishments and hear from guest speaker Dr. Winifred Lender ... worlds. , Dr. Lender, a Santa Barbara psychologist, author ... challenges and benefits of living in the digital age. ...
(Date:10/25/2014)... 25, 2014 Market Research ... Industry, 2009-2019 is a professional and in-depth ... Diagnostics industry. The report firstly reviews the ... classification, application and manufacturing technology. The report ... of Molecular Diagnostics listing their product specification, ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival in ... after his combination drug therapy became too toxic. ... posted on the Surviving Mesothelioma website. , A ... Japan suggests that “maintenance therapy” with pemetrexed may be ... tolerate higher doses of cisplatin. , “Although the ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. ... developed that spot increased risks for certain cancers, one might ... screened. But a new study suggests that, at least ... found out their genes doubled their risk of colon cancer ... get screened. "It didn,t make any difference, not at ...
Breaking Medicine News(10 mins):Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2
... received a $1.5 million grant from the National Institutes ... major role in narcolepsy. ,Narcolepsy is a ... will further Yale research into narcolepsy and other disorders ... ,“The activity of these hypocretin cells is important ...
... a human tumor virus which causes Kaposi’s sarcoma and ... lymphomas with reported median survival time less than six ... of Helsinki have discovered that activation of the p53 ... lymphomas. ,The findings by the research group ...
... Center have found a new method for identifying suspect ... common acute infections in children. ,Traditionally, researchers ... down the virus or bacteria causing it. But that ... not be present in the blood or other easily ...
... to boycott the British Medical journal Lancet by a ... ‘warmongering’ attitude// of Lancet’s parent company Reed Elsevier. ... BMJ (formerly British Medical Journal) Fiona Godlee criticized that ... actually making money out of destroying health. ...
... conducted by Glenn Good and team from University of Missouri, ... of neurological injuries//. While it has been assumed all along ... study offers a new dimension to this issue. ... of their health. But the same quality is said to ...
... hospitals on the model of the All India Institute ... Bhubaneshwar, Jodhpur and Rishikesh under the Pradhan Mantri Swastha ... Welfare Anbumani Ramadoss has said. ,In a ... the Rajya Sabha, the upper House of the Indian ...
Cached Medicine News:Health News:$1.5 Million Grant to Yale for Narcolepsy-Neurotransmitter Study 2Health News:A Novel Treatment for KSHV-infected Lymphomas 2Health News:‘Fingerprints’ to Track Common Infections in Childr 2Health News:‘Fingerprints’ to Track Common Infections in Childr 3
... digital mobile imaging just got better ... and instrumentation. Now using,your C-arm you ... Easily Add Visualization and Navigation Technology, ... Intraoperative Decision Making, Provide a ...
... surgical navigation for Spine ... to integrate C-arm fluoroscopy ... It features automatic registration ... to the patient's anatomy, ...
... 20 years of CT engineering innovation and ... the forefront of the revolution in CT ... data at high speed with superb spatial ... extensive clinical experience and close cooperation with ...
... multislice CT scanners. In addition to the ... in an affordable Dual slice configuration. The ... advanced applications and high performance as the ... can be upgraded to Infinite Detector Technology, ...
Medicine Products: